EN
CN JPN

Hubei Jumpcan's Non-public Offering Approved, Grandall Shanghai Office Retained as the Issuer's Counsel

Grandall Law Firm Release Date: 2015-08-28 Views:

On 26 August 2015, the application for non-public offering filed by Hubei Jumpcan Pharmaceutical Co., Ltd. (“Hubei Jumpcan”) was passed and approved by the Issuance and Examination Committee of the CSRC.

Hubei Jumpcan is a high-tech enterprise engaging in research, development, manufacture and sale of western medicine, traditional Chinese medicine and related health care products.  The company is one of the TOP 100 pharmaceutical enterprises in China.

Hubei Jumpcan intends to offer a limited number of 31,654,000 shares with the total amount up to RMB 642,260,000.  The funds so raised will be applied into the relocation, and the construction of logistics center.

Grandall Shanghai Office has been retained as the issuer’s counsel, with Mr. Yao Yi, Ms. Shan Ying and Mr. Qiao Yingqiang being key Grandall lawyers serving the case.